

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

**Claim 1. (Cancelled)**

**Claim 2. (Cancelled)**

**Claim 3. (Cancelled)**

**Claim 4. (Cancelled)**

**Claim 5. (Cancelled)**

**Claim 6. (Cancelled)**

**Claim 7. (Cancelled)**

**Claim 8. (Cancelled)**

**Claim 9. (Cancelled)**

**Claim 10. (Cancelled)**

**Claim 11. (Cancelled)**

**Claim 12. (Cancelled)**

**Claim 13. (Cancelled)**

**Claim 14. (Cancelled)**

**Claim 15. (Cancelled)**

**Claim 16. (Currently Amended)** A compound ~~Compounds~~ of the formula I according to Claim 1 from the group consisting of

- a) 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-[4-methyl-2-(1-oxypyridin-2-yl)thiazol-5-yl]methanone,
- b) 1-[3-(3-isopropoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-[4-methyl-2-(1-oxypyridin-2-yl)thiazol-5-yl]methanone,
- c) 1-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-[4-methyl-2-(1-oxypyridin-2-yl)thiazol-5-yl]methanone,
- d) 1-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-pyridin-3-ylthiazol-5-yl)methanone,
- e) 1-[3-(3-isopropoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-(4-methyl-2-pyridin-3-ylthiazol-5-yl)methanone,

- f) 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-pyridin-3-ylthiazol-5-yl)methanone,
- g) 1-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-pyridin-2-ylthiazol-5-yl)methanone,
- h) 1-[3-(3-isopropoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-pyridin-2-ylthiazol-5-yl)methanone,
- i) 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-pyridin-2-ylthiazol-5-yl)methanone,
- j) 1-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-(4-methyl-2-pyrazin-2-ylthiazol-5-yl)methanone,
- k) 1-[3-(3-isopropoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-pyrazin-2-ylthiazol-5-yl)methanone,
- l) 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-pyrazin-2-ylthiazol-5-yl)methanone,
- m) 1-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-thiophen-2-ylthiazol-5-yl)methanone,
- n) 1-[3-(3-isopropoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-thiophen-2-ylthiazol-5-yl)methanone,
- o) 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-thiophen-2-ylthiazol-5-yl)methanone,
- p) 1-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-[4-methyl-2-phenylthiazol-5-yl]methanone,
- q) 1-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-[4-methyl-2-(4-methoxyphenyl)thiazol-5-yl]methanone,
- r) 1-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-[4-methyl-2-(4-aminophenyl)thiazol-5-yl]methanone,
- s) 2-[(4-{5-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-carbonyl]-4-methylthiazol-2-yl}phenyl)hydrazono]malononitrile, or
- t) 2-[(4-{5-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-carbonyl]-4-methylthiazol-2-yl}phenyl)hydrazono]-2-(1*H*-tetrazol-5-yl)acetonitrile,

or a pharmaceutically acceptable salt or ~~stereoisomers~~ stereoisomer thereof, or a mixture thereof in all ratios.

**Claim 17. (Canceled)**

**Claim 18. (Canceled)**

**Claim 19. (Currently Amended)** A pharmaceutical composition ~~Medicament~~ comprising at least one compound ~~of the formula I~~ according to Claim 16 ~~+~~ and/or a pharmaceutically usable salt or ~~stereoisomers~~ stereoisomer thereof, including mixtures thereof in all ratios, and, ~~optionally, excipients and/or adjuvants~~ a pharmaceutically acceptable carrier.

**Claim 20. (Cancelled)**

**Claim 21. (Cancelled)**

**Claim 22. (Cancelled)**

**Claim 23. (Cancelled)**

**Claim 24. (Cancelled)**

**Claim 25. (Cancelled)**

**Claim 26. (Cancelled)**

**Claim 27. (Cancelled)**

**Claim 28. (Cancelled)**

**Claim 29. (Cancelled)**

**Claim 30. (Cancelled)**

**Claim 31. (Previously Presented)** A method of inhibiting proliferation of T-cells in a host in need thereof, comprising administering to said host an effective amount of a compound of claim 16 ~~+~~.

**Claim 32. (Cancelled)**